CLINICAL TRIALS AND OBSERVATIONS Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia
نویسندگان
چکیده
1Pediatric Hematology and Oncology, University of Frankfurt, Germany; 2Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany; 3Children’s Cancer Research Institute, St Anna Kinderspital and Children’s Cancer Research Institute (CCRI), Vienna, Austria; 42nd Medical School, Charles University, Prague, Czech Republic; 5Department of Pediatric Hematology and Oncology, University of Münster, Germany
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
Preclinical models have demonstrated the efficacy of granulocyte-macrophage colony-stimulating factor-secreting cancer immunotherapies (GVAX platform) accompanied by immunotherapy-primed lymphocytes after autologous stem cell transplantation in hematologic malignancies. We conducted a phase 2 study of this combination in adult patients with acute myeloid leukemia. Immunotherapy consisted of aut...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
The optimal induction for older adults with acute myeloid leukemia (AML) is unknown. Several anthracyclines have been proposed, but the data remain equivocal. Additionally, few prospective trials of priming with hematopoietic growth factors to cycle leukemia cells prior to induction chemotherapy have been conducted. Three hundred and sixtytwo older adults with previously untreated AML were rand...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
The treatment of older patients with acute myeloid leukemia (AML) remains unsatisfactory, with complete remission (CR) achieved in only approximately 50% and long-term disease-free survival in 10% to 20%. Three hundred eighty-eight patients (60 years of age and older) with newly diagnosed de novo AML were randomly assigned to receive placebo (P) or granulocyte-macrophage colony-stimulating fact...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children
Long-term survivors of acquired aplastic anemia (AA) have an increased risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST). It is uncertain whether the increased survival time simply discloses the natural history of AA as a premalignant disease or whether secondary disease is related to the therapy itself. Between November 199...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
Thomas Pabst,1 Edo Vellenga,2 Wim van Putten,3 Harry C. Schouten,4 Carlos Graux,5 Marie-Christiane Vekemans,6 Bart Biemond,7 Peter Sonneveld,8 Jakob Passweg,9 Leo Verdonck,10 Marie-Cecile Legdeur,11 Matthias Theobald,12 Emanuel Jacky,13 Mario Bargetzi,14 Johan Maertens,15 Gert Jan Ossenkoppele,16 and Bob Löwenberg,8 for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), the German AML...
متن کامل